HIV drug could offer yearlong protection with a single shot
A new formulation of Gilead's HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the pharmacokinetics, safety and tolerability of two intramuscular formations of lenacapavir in participants ages 18-55 without HIV.
2d
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study by researchers ...
The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
1don MSN
Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback